Ingevity reports third quarter 2021 financial results

Rhea-AI Summary

Ingevity Corporation (NYSE:NGVT) reported third quarter 2021 net sales of $376.8 million, reflecting a 13.6% increase year-over-year. The company experienced a net loss of $4.2 million due to an $85 million pre-tax litigation expense. Adjusted earnings reached $64.4 million, with adjusted EPS of $1.62. Adjusted EBITDA was $119.5 million, a decline of 6.3%. The revised full-year guidance for sales is projected between $1.320 billion and $1.360 billion with adjusted EBITDA of $405 million to $420 million. The company cited challenges from the ongoing microchip shortage impacting automotive production.

Positive

• Third quarter net sales reached $376.8 million, up 13.6% year-over-year.
• Adjusted EBITDA of $119.5 million, despite a 6.3% decrease.
• Operating cash flow of $100.1 million led to free cash flow of $74.6 million.
• Sales in Performance Chemicals segment increased by 37.7%, driven by higher demand.

Negative

• Net loss of $4.2 million includes an $85 million litigation expense.
• Adjusted earnings decreased by 13.2% compared to the prior year quarter.
• Performance Materials sales down 17.9% due to microchip shortage impacting automotive production.

HIGHLIGHTS: (comparisons versus prior year period)

• Third quarter net sales of $376.8 million, up 13.6%
• Net loss of $4.2 million reflects an $85 million pre-tax expense for a litigation verdict, which had an after-tax impact on earnings of $1.64 per share
• Adjusted earnings of $64.4 million and adjusted earnings per share of $1.62
• Adjusted EBITDA of $119.5 million and adjusted EBITDA margin of 31.7%
• Operating cash flow of $100.1 million drove free cash flow of $74.6 million
• Company updates full year 2021 guidance to sales between $1.320 billion and $1.360 billion and adjusted EBITDA between $405 million and $420 million

The results and guidance in this release include non-GAAP financial measures. Refer to the section entitled “Use of non-GAAP financial measures” within this release.

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)-- Ingevity Corporation (NYSE:NGVT) today reported its third quarter 2021 financial results.

Third quarter net sales of $376.8 million rose 13.6% versus the prior year third quarter. Net loss of $4.2 million included a pre-tax expense of $85 million to record a previously disclosed adverse litigation verdict. Third quarter diluted loss per share was $0.11 compared to diluted earnings per share (EPS) of $1.69 in the prior year period.

Adjusted earnings of $64.4 million decreased 13.2% versus the prior year quarter. Diluted adjusted EPS were $1.62, which exclude, net of tax, $0.09 related to restructuring and other charges, net, and $1.64 of litigation-related expense recognized during the quarter. This compares to diluted adjusted EPS of $1.79 in the prior year quarter. Compared to third quarter of last year, adjusted EBITDA of $119.5 million decreased 6.3% and adjusted EBITDA margin of 31.7% decreased 680 basis points. Operating cash flow of $100.1 million drove free cash flow that was up 1.5% to $74.6 million.

“Our third quarter results were driven by markedly higher Performance Chemicals volumes in Engineered Polymers and Industrial Specialties and were supported by price increases across the segment,” said John Fortson, president and CEO. “The prolonged impact of the global microchip shortage continues to depress automotive production, negatively impacting our activated carbon product sales. As a result, Performance Materials sales and adjusted EBITDA were down compared to 2020’s third quarter when demand and production rebounded sharply from pandemic lows.” Fortson also commented that the significant mix shift in total revenue, with Performance Chemicals up 38% and Performance Materials down 18%, drove the decline in consolidated margins.

“We also faced challenges from rising raw materials costs and supply chain disruptions,” added Fortson. “I am proud of how the company continues to successfully navigate and execute in this dynamic environment.”

Performance Chemicals

Third quarter 2021 sales in the Performance Chemicals segment were $258.7 million, up 37.7% versus the third quarter 2020. Segment adjusted EBITDA was $63.1 million, up 33.7% versus the prior year quarter primarily due to significantly higher volume and prices, partially offset by increasing costs primarily due to raw materials and logistics inflation. Segment EBITDA margin was 24.4%.

“In Performance Chemicals, sales in Engineered Polymers and Industrial Specialties rose significantly versus the prior year quarter and we were encouraged to see continued demand for higher-value derivative products across the segment,” said Fortson.

Demand for Engineered Polymers products continues to recover from depressed 2020 pandemic levels. Quarterly sales were up over 100% versus the prior year quarter due to increased global volume in all applications, particularly in automotive and industrial markets. Sales in Industrial Specialties applications rose more than 40% due to strengthening adhesives, dispersants, lubricants and oilfield markets. The business also implemented additional price increases for tall oil rosin and tall oil fatty acid products. Pavement Technologies sales were also ahead of the prior year quarter.

Performance Materials

Third quarter 2021 sales in the Performance Materials segment were $118.1 million, down 17.9% versus the third quarter of 2020. Segment adjusted EBITDA was $56.4 million, down 29.9% versus the prior year period as the microchip shortage and supply chain issues continue to negatively impact automotive production. Segment EBITDA margin was 47.8%.

“Sales of our activated carbon products were negatively impacted by lower automotive production due to the shortage of microchips affecting the auto industry on a global scale,” said Fortson. “In the third quarter, North America vehicle production declined 27% and light vehicle inventories as of the end of September fell 64% to less than one million vehicles compared to 2.7 million vehicles available in September 2020. Compared to the prior year quarter, China light vehicle production and sales were also down almost 15%.”

Revised Guidance

Ingevity’s updated guidance for full year 2021 is sales between $1.320 billion to $1.360 billion and adjusted EBITDA between $405 million to $420 million.

“Our revised guidance for the remainder of the year reflects our lowered expectations for Performance Materials and our confidence in the continued strong demand for products in our Performance Chemicals portfolio,” said Fortson. “While we expect an ongoing shortage of microchips, continued logistics headwinds and raw materials and energy inflation to be challenges throughout the rest of the year, we believe strongly in our team’s proven ability to operate efficiently and effectively.”

Ingevity: Purify, Protect and Enhance

Ingevity provides products and technologies that purify, protect, and enhance the world around us. Through a team of talented and experienced people, we develop, manufacture and bring to market solutions that help customers solve complex problems and make the world more sustainable. We operate in two reporting segments: Performance Chemicals, which includes specialty chemicals and engineered polymers; and Performance Materials, which includes high-performance activated carbon. These products are used in a variety of demanding applications, including asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, publication inks, coatings, elastomers, bioplastics and automotive components that reduce gasoline vapor emissions. Headquartered in North Charleston, South Carolina, Ingevity operates from 25 locations around the world and employs approximately 1,850 people. The company is traded on the New York Stock Exchange (NYSE: NGVT). For more information visit www.ingevity.com.

Additional Information

The company will host a live webcast on Thursday, October 28, 2021, at 10 a.m. (Eastern) to discuss third quarter 2021 fiscal results. The webcast can be accessed through the investors section of Ingevity’s website, or via this link: Ingevity Q3 2021 earnings webcast. You may also listen to the conference call by dialing 877-407-2991 (inside the U.S.) or 201-389-0925 (outside the U.S.), at least 10 minutes prior to the start of the event. Information on how to access the webcast and conference call, along with a slide deck containing other relevant financial and statistical information, will be posted to the investors section of Ingevity’s website prior to the call. For those unable to join the live event, a replay of the webcast will be available beginning at approximately 2 p.m. (Eastern) on October 28, 2021, through November 24, 2021: Ingevity Q3 2021 earnings webcast replay.

Use of non-GAAP financial measures: This presentation includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this presentation. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided.

Cautionary statements about forward-looking statements: This press release contains “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements generally include the words “will,” “plans,” “intends,” “targets,” “expects,” “outlook,” or similar expressions. Forward-looking statements may include, without limitation, expected financial positions, results of operations and cash flows; financing plans; business strategies and expectations; operating plans; impact of COVID-19; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost-reduction initiatives, plans and objectives; litigation related strategies and outcomes; markets for securities and expected future repurchases of shares, including statements about the manner, amount and timing of repurchases. Actual results could differ materially from the views expressed. Factors that could cause actual results to materially differ from those contained in the forward-looking statements, or that could cause other forward-looking statements to prove incorrect, include, without limitation, adverse effects from the COVID-19 pandemic; adverse effects of general economic and financial conditions; risks related to international sales and operations; impacts of currency exchange rates and currency devaluation; compliance with U.S. and foreign regulations concerning our operations; changes in trade policy, including the imposition of tariffs; adverse conditions in the global automotive market or adoption of alternative and new technologies; competition from producers of alternative products and new technologies, and new or emerging competitors; competition from infringing intellectual property activity; worldwide air quality standards; a decrease in government infrastructure spending; the impact of adverse conditions in cyclical end markets on demand for engineered polymers products; declining volumes and downward pricing in the printing inks market; the limited supply of or lack of access to sufficient crude tall oil; a prolonged period of low energy prices; the impact of the United Kingdom’s withdrawal from the European Union; exposure to unknown or understated liabilities from the acquisition of the Perstorp Holding AB’s Capa® caprolactone business; the provision of services by third parties at several facilities; supply chain disruptions; natural disasters, such as hurricanes, winter or tropical storms, earthquakes, tornados, floods, fires; other unanticipated problems such as labor difficulties, equipment failure or unscheduled maintenance and repair; attracting and retaining key personnel; protection of intellectual property and proprietary information; information technology security breaches and other disruptions; complications with designing and implementing our new enterprise resource planning system; adverse litigation judgments and related costs; government policies and regulations, including, but not limited to, those affecting the environment, climate change, tax policies, tariffs and the chemicals industry; and lawsuits arising out of environmental damage or personal injuries associated with chemical or other manufacturing processes, and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our Annual Report on Form 10-K, our Form 10-Q for the quarter ended March 31, 2021, and other periodic filings. These forward-looking statements speak only as of the date of this press release. Ingevity assumes no obligation to provide any revisions to, or update, any projections and forward-looking statements contained in this press release.

INGEVITY CORPORATION
Condensed Consolidated Statements of Operations (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
In millions, except per share data	2021				2020				2021				2020
Net sales	$	376.8			$	331.7			$	1,055.5			$	890.5
Cost of sales	235.0				192.1				647.7				552.4
Gross profit	141.8				139.6				407.8				338.1
Selling, general, and administrative expenses	43.5				34.9				131.0				107.9
Research and technical expenses	6.8				5.2				19.3				16.8
Restructuring and other (income) charges, net	4.1				5.5				12.3				13.3
Acquisition-related costs	0.2				—				0.9				1.7
Other (income) expense, net	84.6				(3.0)				81.6				(0.1)
Interest expense, net	11.6				8.9				36.2				29.8
Income (loss) before income taxes	(9.0)				88.1				126.5				168.7
Provision (benefit) for income taxes	(4.8)				18.2				37.7				33.3
Net income (loss)	$	(4.2)			$	69.9			$	88.8			$	135.4
Per share data
Basic earnings (loss) per share	$	(0.11)			$	1.69			$	2.22			$	3.27
Diluted earnings (loss) per share	(0.11)				1.69				2.21				3.26
Weighted average shares outstanding
Basic	39.5				41.3				40.0				41.4
Diluted	39.5				41.5				40.2				41.6

INGEVITY CORPORATION
Segment Operating Results (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
In millions	2021				2020				2021				2020
Net sales
Performance Materials (1)	$	118.1			$	143.8			$	384.8			$	349.3
Performance Chemicals	$	258.7			$	187.9			$	670.7			$	541.2
Pavement Technologies product line	73.2				72.5				162.4				157.1
Industrial Specialties product line (1)	132.6				90.1				364.7				290.9
Engineered Polymers product line	52.9				25.3				143.6				93.2
Total net sales	$	376.8			$	331.7			$	1,055.5			$	890.5
Segment EBITDA (2)
Performance Materials	$	56.4			$	80.4			$	191.4			$	164.9
Performance Chemicals	63.1				47.2				151.2				122.1
Total segment EBITDA (2)	$	119.5			$	127.6			$	342.6			$	287.0
Interest expense, net	(11.6)				(8.9)				(36.2)				(29.8)
(Provision) benefit for income taxes	4.8				(18.2)				(37.7)				(33.3)
Depreciation and amortization - Performance Materials	(8.9)				(8.0)				(26.9)				(22.5)
Depreciation and amortization - Performance Chemicals	(18.7)				(17.1)				(54.8)				(51.0)
Restructuring and other income (charges), net (3)	(4.1)				(5.5)				(12.3)				(13.3)
Acquisition and other-related costs (4)	(0.2)				—				(0.9)				(1.7)
Litigation expense (5)	(85.0)				—				(85.0)				—
Net income (loss)	$	(4.2)			$	69.9			$	88.8			$	135.4

_______________
(1)		Beginning in Q1 2021, we updated disaggregated revenue disclosures, combining certain product groups to reflect categories that depict how the nature, amount, and uncertainty of revenue and cash flows are affected by economic factors. As the result, Automotive Technologies and Process Purification product lines have been combined within the Performance Materials segment. Similarly, Oilfield Technologies product line has been combined with the Industrial Specialties product line within the Performance Chemicals segment.
(2)		Segment EBITDA is the primary measure used by our chief operating decision maker to evaluate the performance of and allocate resources among our operating segments. Segment EBITDA is defined as segment revenue less segment operating expenses (segment operating expenses consist of costs of sales, selling, general and administrative expenses, other (income) expense, net, excluding depreciation and amortization). We have excluded the following items from segment EBITDA: interest expense, net associated with corporate debt facilities, income taxes, depreciation, amortization, restructuring and other (income) charges, net, acquisition and other-related costs, certain litigation expenses, pension and postretirement settlement and curtailment (income) charges.
(3)		Income (charges) for all periods presented relate to restructuring activity and costs associated with the business transformation initiative. For the three and nine months ended September 30, 2021, charges of $1.1 million and $4.5 million relate to the Performance Materials segment and charges of $3.0 million and $7.8 million relate to the Performance Chemicals segment, respectively. For the three and nine months ended September 30, 2020, charges of $2.6 million and $5.4 million relate to the Performance Materials segment and charges of $2.9 million and $7.9 million relate to the Performance Chemicals segment, respectively.
(4)		For the three and nine months ended September 30, 2021, charges of zero and $0.2 million relate to the acquisition of a strategic investment in the Performance Materials segment and charges of $0.2 million and $0.7 million relate to the integration of the Perstorp Capa business into our Performance Chemicals segment, respectively. For the three and nine months ended September 30, 2020, all charges relate to the integration of the Perstorp Capa business into our Performance Chemicals segment.
(5)		For the three and nine months ended September 30, 2021, litigation expense relates to the Performance Materials segment.

INGEVITY CORPORATION
Condensed Consolidated Balance Sheets (Unaudited)
In millions	September 30, 2021				December 31, 2020
Assets
Cash and cash equivalents	$	269.4			$	257.7
Accounts receivable, net	175.8				148.0
Inventories, net	228.3				189.0
Prepaid and other current assets	46.8				34.0
Current assets	720.3				628.7
Property, plant and equipment, net	701.2				703.6
Goodwill	440.7				445.3
Other intangibles, net	344.8				373.3
Restricted investment	75.5				73.6
Other assets	143.7				110.0
Total Assets	$	2,426.2			$	2,334.5
Liabilities
Accounts payable	$	127.4			$	104.2
Accrued expenses	46.1				46.6
Other current liabilities	74.1				72.6
Current liabilities	247.6				223.4
Long-term debt including finance lease obligations	1,254.4				1,267.4
Deferred income taxes	116.3				117.0
Other liabilities	163.4				84.6
Total Liabilities	1,781.7				1,692.4
Equity	644.5				642.1
Total Liabilities and Equity	$	2,426.2			$	2,334.5

INGEVITY CORPORATION
Condensed Consolidated Statements of Cash Flows (Unaudited)
	Nine Months Ended September 30,
In millions	2021				2020
Cash provided by (used in) operating activities:
Net income (loss)	$	88.8			$	135.4
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:
Depreciation and amortization	81.7				73.5
Other non-cash items	31.1				44.1
Changes in operating assets and liabilities, net of effect of acquisitions:
Changes in other operating assets and liabilities, net	15.4				(53.9)
Net cash provided by (used in) operating activities	$	217.0			$	199.1
Cash provided by (used in) investing activities:
Capital expenditures	$	(66.4)			$	(51.0)
Finance lease expenditures	—				(23.8)
Purchase of strategic investments	(16.5)				—
Other investing activities, net	(0.5)				(3.6)
Net cash provided by (used in) investing activities	$	(83.4)			$	(78.4)
Cash provided by (used in) financing activities:
Proceeds from revolving credit facility	$	—			$	346.1
Payments on revolving credit facility	—				(307.3)
Payments on long-term borrowings	(18.8)				(14.1)
Finance lease obligations, net	(0.6)				23.3
Borrowings (repayments) of notes payable and other short-term borrowings, net	(1.9)				(0.9)
Tax payments related to withholdings on vested equity awards	(2.4)				(3.0)
Proceeds and withholdings from share-based compensation plans, net	3.7				3.1
Repurchases of common stock under publicly announced plan	(100.3)				(32.4)
Net cash provided by (used in) financing activities	$	(120.3)			$	14.8
Increase (decrease) in cash, cash equivalents, and restricted cash	13.3				135.5
Effect of exchange rate changes on cash	(1.8)				0.3
Change in cash, cash equivalents, and restricted cash(1)	11.5				135.8
Cash, cash equivalents, and restricted cash at beginning of period	258.4				64.6
Cash, cash equivalents, and restricted cash at end of period (1)	$	269.9			$	200.4
(1) Includes restricted cash of $0.5 million and $2.2 million and cash and cash equivalents of $269.4 million and $198.2 million at September 30, 2021 and 2020, respectively. Restricted cash is included within "Prepaid and other current assets" within the condensed consolidated balance sheets.
Supplemental cash flow information:
Cash paid for interest, net of capitalized interest	$	35.5			$	37.7
Cash paid for income taxes, net of refunds	43.2				41.4
Purchases of property, plant and equipment in accounts payable	5.9				1.9
Leased assets obtained in exchange for new finance lease liabilities	—				23.8
Leased assets obtained in exchange for new operating lease liabilities	14.7				24.5

Ingevity Corporation

Non-GAAP Financial Measures

Ingevity has presented certain financial measures, defined below, which have not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and has provided a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP on the following pages. These financial measures are not meant to be considered in isolation or as a substitute for the most directly comparable financial measure calculated in accordance with GAAP. Investors should consider the limitations associated with these non-GAAP measures, including the potential lack of comparability of these measures from one company to another.

We believe these non-GAAP financial measures provide management as well as investors, potential investors, securities analysts and others with useful information to evaluate the performance of the business, because such measures, when viewed together with our financial results computed in accordance with GAAP, provide a more complete understanding of the factors and trends affecting our historical financial performance and projected future results.

Ingevity uses the following non-GAAP measures:

Adjusted earnings (loss) is defined as net income (loss) plus restructuring and other (income) charges, net, acquisition and other-related costs, certain litigation expenses, pension and postretirement settlement and curtailment (income) charges and the income tax expense (benefit) on those items, less the provision (benefit) from certain discrete tax items.

Diluted adjusted earnings (loss) per share is defined as diluted earnings (loss) per common share plus restructuring and other (income) charges, net per share, acquisition and other-related costs per share, certain litigation expenses per share, pension and postretirement settlement and curtailment (income) charges per share and the income tax expense (benefit) per share on those items, less the per share tax provision (benefit) from certain discrete tax items per share.

Adjusted EBITDA is defined as net income (loss) plus interest expense, net, provision (benefit) for income taxes, depreciation, amortization, restructuring and other (income) charges, net, acquisition and other-related costs, certain litigation expenses, pension and postretirement settlement and curtailment (income) charges, net.

Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Net sales.

Free Cash Flow is defined as the sum of cash provided by (used in) the following items: operating activities less capital expenditures.

Net Debt is defined as the sum of notes payable, short-term debt, current maturities of long-term debt and long-term debt less the sum of cash and cash equivalents, restricted cash associated with our New Market Tax Credit financing arrangement, and restricted investment.

Net Debt Ratio is defined as Net Debt divided by last twelve months Adjusted EBITDA, inclusive of acquisition-related pro forma adjustments.

Ingevity also uses the above financial measures as the primary measures of profitability used by managers of the business. In addition, Ingevity believes Adjusted EBITDA and Adjusted EBITDA Margin are useful measures because they exclude the effects of financing and investment activities as well as non-operating activities.

GAAP Reconciliation of 2021 Adjusted EBITDA Guidance

A reconciliation of net income to adjusted EBITDA as projected for 2021 is not provided. Ingevity does not forecast net income as it cannot, without unreasonable effort, estimate or predict with certainty various components of net income. These components, net of tax, include further restructuring and other income (charges), net; additional acquisition and other-related costs; certain litigation expenses; additional pension and postretirement settlement and curtailment (income) charges; and revisions due to legislative tax rate changes. Additionally, discrete tax items could drive variability in our projected effective tax rate. All of these components could significantly impact such financial measures. Further, in the future, other items with similar characteristics to those currently included in adjusted EBITDA, that have a similar impact on comparability of periods, and which are not known at this time, may exist and impact adjusted EBITDA.

 

INGEVITY CORPORATION Reconciliation of Non-GAAP Financial Measures
Reconciliation of Net Income (Loss) (GAAP) to Adjusted Earnings (Loss) (Non-GAAP)
	Three Months Ended September 30,								Nine Months Ended September 30,
In millions, except per share data (unaudited)	2021				2020				2021				2020
Net income (loss) (GAAP)	$	(4.2)			$	69.9			$	88.8			$	135.4
Restructuring and other (income) charges, net	4.1				5.5				12.3				13.3
Acquisition and other-related costs	0.2				—				0.9				1.7
Litigation expense	85.0				—				85.0				—
Tax effect on items above	(20.7)				(1.2)				(22.7)				(3.4)
Certain discrete tax provision (benefit) (1)	—				—				14.3				0.5
Adjusted earnings (loss) (Non-GAAP)	$	64.4			$	74.2			$	178.6			$	147.5
Diluted earnings (loss) per common share (GAAP)	$	(0.11)			$	1.69			$	2.21			$	3.26
Restructuring and other (income) charges, net	0.10				0.13				0.30				0.32
Acquisition and other-related costs	0.01				—				0.02				0.04
Litigation expense	2.14				—				2.11				—
Tax effect on items above	(0.52)				(0.03)				(0.56)				(0.08)
Certain discrete tax provision (benefit)	—				—				0.36				0.01
Diluted adjusted earnings (loss) per share (Non-GAAP)	$	1.62			$	1.79			$	4.44			$	3.55
Weighted average common shares outstanding - Diluted	39.8				41.5				40.2				41.6

_______________

(1) Represents certain discrete tax items such as excess tax benefits on stock compensation and impacts of legislative tax rate changes. Management believes excluding these discrete tax items assists investors, potential investors, securities analysts, and others in understanding the tax provision and the effective tax rate related to continuing operating results thereby providing useful supplemental information about operational performance.

INGEVITY CORPORATION Reconciliation of Non-GAAP Financial Measures
Reconciliation of Net Income (Loss) (GAAP) to Adjusted EBITDA (Non-GAAP)
	Three Months Ended September 30,								Nine Months Ended September 30,
In millions, except percentages (unaudited)	2021				2020				2021				2020
Net income (loss) (GAAP)	$	(4.2)			$	69.9			$	88.8			$	135.4
Interest expense, net	11.6				8.9				36.2				29.8
Provision (benefit) for income taxes	(4.8)				18.2				37.7				33.3
Depreciation and amortization	27.6				25.1				81.7				73.5
Restructuring and other (income) charges, net	4.1				5.5				12.3				13.3
Acquisition and other-related costs	0.2				—				0.9				1.7
Litigation expense	85.0				—				85.0				—
Adjusted EBITDA (Non-GAAP)	$	119.5			$	127.6			$	342.6			$	287.0
Net sales	$	376.8			$	331.7			$	1,055.5			$	890.5
Net income (loss) margin	(1.1)		%		21.1		%		8.4		%		15.2		%
Adjusted EBITDA margin	31.7		%		38.5		%		32.5		%		32.2		%

INGEVITY CORPORATION Reconciliation of Non-GAAP Financial Measures
Calculation of Free Cash Flow (Non-GAAP)
	Three Months Ended September 30,								Nine Months Ended September 30,
In millions (unaudited)	2021				2020				2021				2020
Cash Flow from Operations (GAAP)	$	100.1			$	90.0			$	217.0			$	199.1
Less: Capital expenditures	25.5				16.5				66.4				51.0
Free Cash Flow (Non-GAAP)	$	74.6			$	73.5			$	150.6			$	148.1

INGEVITY CORPORATION Reconciliation of Non-GAAP Financial Measures
Calculation of Net Debt to Adjusted EBITDA Ratio (Non-GAAP)
In millions, except ratios (unaudited)	September 30, 2021
Notes payable and current maturities of long-term debt	$	19.5
Long-term debt including finance lease obligations	1,254.4
Debt issuance costs	11.5
Total Debt	1,285.4
Less:
Cash and cash equivalents (1)	269.7
Restricted investment	75.5
Net Debt	$	940.2
Net Debt Ratio (Non GAAP)
Adjusted EBITDA (2)
Twelve months ended December 31, 2020	$	397.9
Nine months ended September 30, 2020	(287.0)
Nine months ended September 30, 2021	342.6
Adjusted EBITDA - last twelve months (LTM) as of September 30, 2021	$	453.5
Net debt ratio (Non GAAP)	2.1x

(1) Includes $0.3 million of Restricted Cash related to the New Market Tax Credit arrangement.

(2) Refer to the Reconciliation of Net Income (GAAP) to Adjusted EBITDA (Non-GAAP) schedule for the reconciliation to the most comparable GAAP financial measure.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027006081/en/

Caroline Monahan

843-740-2068

media@ingevity.com



Investors:

Bill Hamilton

843-740-2138

investors@ingevity.com

Source: Ingevity Corporation

FAQ

What were Ingevity's Q3 2021 earnings results?

Ingevity reported Q3 2021 net sales of $376.8 million, a net loss of $4.2 million, and adjusted earnings of $64.4 million.

What is Ingevity's updated full-year guidance for 2021?

Ingevity's revised full-year guidance expects sales between $1.320 billion and $1.360 billion and adjusted EBITDA between $405 million and $420 million.

How did the microchip shortage affect Ingevity's performance?

The microchip shortage led to a decline in automotive production, negatively impacting sales in the Performance Materials segment, which were down 17.9%.